AR083256A1 - Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico - Google Patents
Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilicoInfo
- Publication number
- AR083256A1 AR083256A1 ARP110103617A ARP110103617A AR083256A1 AR 083256 A1 AR083256 A1 AR 083256A1 AR P110103617 A ARP110103617 A AR P110103617A AR P110103617 A ARP110103617 A AR P110103617A AR 083256 A1 AR083256 A1 AR 083256A1
- Authority
- AR
- Argentina
- Prior art keywords
- solid state
- ppm
- forms
- ciclobutil
- cyclopentil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Formas de la sal de sodio del compuesto de fórmula (1), y métodos para su preparación, sus composiciones farmacéuticas, y su uso en el tratamiento de la infección por el Virus de la Hepatitis C (VHC).Reivindicación 2: Una sal cristalina de sodio de acuerdo con la reivindicación 1, caracterizada porque tiene: (a) un modelo de difracción de rayos X en polvo que comprende picos a 7,5 y 20,4 grados 2q (± 0,2 grados 2q) cuando se mide usando radiación CuKa; o (b) un espectro 13C RMN en estado sólido que comprende picos a un desplazamiento químico de 176,8 y 168,4 ppm (± 0,2 ppm); o bien (c) ambos un modelo de difracción de rayos X en polvo que comprende picos a 7,5 y 20,4 grados 2q (± 0,2 grados 2q) cuando se mide usando radiación CuKa y un espectro 13C RMN en estado sólido que comprende picos a un desplazamiento químico de 176,8 ppm y 168,4 ppm (± 0,2 ppm).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38824210P | 2010-09-30 | 2010-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083256A1 true AR083256A1 (es) | 2013-02-13 |
Family
ID=44759789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103617A AR083256A1 (es) | 2010-09-30 | 2011-09-29 | Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico |
Country Status (21)
Country | Link |
---|---|
US (2) | US8598183B2 (es) |
EP (1) | EP2621921A1 (es) |
JP (1) | JP2013543495A (es) |
KR (1) | KR20130108326A (es) |
CN (1) | CN103153987A (es) |
AP (1) | AP2013006733A0 (es) |
AR (1) | AR083256A1 (es) |
AU (1) | AU2011307346A1 (es) |
BR (1) | BR112013007700A2 (es) |
CA (1) | CA2813179A1 (es) |
CL (1) | CL2013000578A1 (es) |
CO (1) | CO6700844A2 (es) |
EA (1) | EA201300422A1 (es) |
EC (1) | ECSP13012552A (es) |
MA (1) | MA34548B1 (es) |
MX (1) | MX2013003551A (es) |
PE (1) | PE20131351A1 (es) |
SG (1) | SG188376A1 (es) |
TW (1) | TW201307327A (es) |
UY (1) | UY33632A (es) |
WO (1) | WO2012044520A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8598183B2 (en) * | 2010-09-30 | 2013-12-03 | Boehringer Ingelheim International Gmbh | Solid state forms of a potent HCV inhibitor |
RU2631320C2 (ru) * | 2011-12-06 | 2017-09-21 | Санофи | Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты |
US20130261134A1 (en) * | 2012-03-30 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Mesylate salt forms of a potent hcv inhibitor |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033128B2 (en) | 1993-09-28 | 2011-11-23 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
US5821242A (en) * | 1996-06-06 | 1998-10-13 | Eli Lilly And Company | Anti-viral compounds |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
DK1718608T3 (da) | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
CA2597680A1 (en) | 2005-02-11 | 2006-08-17 | Boehringer Ingelheim International Gmbh | Process for preparing 2,3-disubstituted indoles |
KR101374928B1 (ko) | 2005-11-09 | 2014-03-14 | 노파르티스 아게 | 일시적 가소제를 사용한 약학 조성물의 제조 방법 |
US8598183B2 (en) * | 2010-09-30 | 2013-12-03 | Boehringer Ingelheim International Gmbh | Solid state forms of a potent HCV inhibitor |
-
2011
- 2011-09-23 US US13/241,551 patent/US8598183B2/en active Active
- 2011-09-23 EP EP11764925.1A patent/EP2621921A1/en not_active Withdrawn
- 2011-09-23 CN CN2011800471790A patent/CN103153987A/zh active Pending
- 2011-09-23 MX MX2013003551A patent/MX2013003551A/es not_active Application Discontinuation
- 2011-09-23 EA EA201300422A patent/EA201300422A1/ru unknown
- 2011-09-23 SG SG2013015854A patent/SG188376A1/en unknown
- 2011-09-23 KR KR1020137008249A patent/KR20130108326A/ko not_active Application Discontinuation
- 2011-09-23 BR BR112013007700A patent/BR112013007700A2/pt not_active IP Right Cessation
- 2011-09-23 PE PE2013000628A patent/PE20131351A1/es not_active Application Discontinuation
- 2011-09-23 WO PCT/US2011/052869 patent/WO2012044520A1/en active Application Filing
- 2011-09-23 JP JP2013531669A patent/JP2013543495A/ja active Pending
- 2011-09-23 MA MA35773A patent/MA34548B1/fr unknown
- 2011-09-23 AU AU2011307346A patent/AU2011307346A1/en not_active Abandoned
- 2011-09-23 CA CA2813179A patent/CA2813179A1/en not_active Abandoned
- 2011-09-23 AP AP2013006733A patent/AP2013006733A0/xx unknown
- 2011-09-29 TW TW100135337A patent/TW201307327A/zh unknown
- 2011-09-29 AR ARP110103617A patent/AR083256A1/es unknown
- 2011-09-29 UY UY0001033632A patent/UY33632A/es unknown
-
2013
- 2013-02-28 CL CL2013000578A patent/CL2013000578A1/es unknown
- 2013-03-22 CO CO13057890A patent/CO6700844A2/es unknown
- 2013-04-15 EC ECSP13012552 patent/ECSP13012552A/es unknown
- 2013-10-30 US US14/067,218 patent/US20140057928A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011307346A1 (en) | 2013-02-21 |
EP2621921A1 (en) | 2013-08-07 |
SG188376A1 (en) | 2013-04-30 |
BR112013007700A2 (pt) | 2019-09-24 |
CO6700844A2 (es) | 2013-06-28 |
JP2013543495A (ja) | 2013-12-05 |
CN103153987A (zh) | 2013-06-12 |
CL2013000578A1 (es) | 2013-08-02 |
UY33632A (es) | 2012-04-30 |
TW201307327A (zh) | 2013-02-16 |
US20120122887A1 (en) | 2012-05-17 |
MX2013003551A (es) | 2013-05-01 |
WO2012044520A1 (en) | 2012-04-05 |
CA2813179A1 (en) | 2012-04-05 |
ECSP13012552A (es) | 2013-06-28 |
PE20131351A1 (es) | 2013-12-04 |
AP2013006733A0 (en) | 2013-02-28 |
MA34548B1 (fr) | 2013-09-02 |
US20140057928A1 (en) | 2014-02-27 |
EA201300422A1 (ru) | 2013-09-30 |
KR20130108326A (ko) | 2013-10-02 |
US8598183B2 (en) | 2013-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
ECSP088859A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
CY1118726T1 (el) | Αναστολεις αντιγραφης ιων γριπης | |
AR080494A1 (es) | Sales cristalinas de un potente inhibidor del hcv y composiciones farmaceuticas que las contienen | |
RU2013109393A (ru) | Безилатная соль ингибитора втк | |
WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
BRPI0603043A (pt) | forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a | |
CR8647A (es) | Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen | |
HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
HRP20130026T1 (hr) | Kristalni oblik posakonazola | |
AR066158A1 (es) | COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE. | |
BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
MY143557A (en) | Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it | |
AR073769A1 (es) | Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih. | |
AR083256A1 (es) | Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico | |
EA200801777A1 (ru) | α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ | |
TR201902057T4 (tr) | Tetrasiklin bileşikleri. | |
AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
BRPI0606923A2 (pt) | substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica | |
IN2012DN06678A (es) | ||
CR20120655A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen | |
CY1120728T1 (el) | Παραγωγα διαζεπινονης χρησιμα για τη θεραπεια του συνδρομου ευθραυστου χ, της νοσου toy parkinson ή της γαστρο-οισοφαγικης παλινδρομησης | |
WO2008102037A8 (es) | Uso de compuestos como inhibidores de la flavodoxina de helicobacter | |
TH124708B (th) | รูปผลึกของสารยับยั้งออกฤทธิ์ต้าน hcv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |